Synergism between anti-angiogenic and immune checkpoint inhibitor drugs: A hypothesis

Area of Science:

• Oncology
• Immunology
• Cancer Biology

Background:

• Hepatocellular cancer (HCC) and renal cell cancer (RCC) exhibit resistance to traditional chemotherapy.
• Therapies targeting tumor stroma have improved management of these cancers.
• Combining anti-angiogenic (AA) agents with immune checkpoint inhibitors (ICIs) shows significant promise.

Purpose of the Study:

• To explore the synergistic mechanisms of bevacizumab and atezolizumab in treating HCC and RCC.
• To investigate the hypothesis that bevacizumab-induced hypoxia enhances tumor mutational burden, increasing sensitivity to ICIs.
• To evaluate bevacizumab's potential role in mitigating ICI-induced hyperprogression.

Main Methods:

• Review of recent clinical trial data (IMbrave150, IMmotion151).
• Analysis of proposed biological mechanisms linking bevacizumab, hypoxia, and immune response.
• Exploration of bevacizumab's effect on tumor microenvironment and mutational landscape.

Main Results:

• Combination therapy with AA agents and ICIs demonstrates superior outcomes compared to targeted agents.
• Bevacizumab may enhance ICI efficacy by improving tissue perfusion and modulating the tumor microenvironment.
• An alternative hypothesis suggests bevacizumab-induced hypoxia increases tumor mutational burden, enhancing ICI effectiveness.

Conclusions:

• Bevacizumab combined with ICIs represents a significant advancement in HCC and RCC treatment.
• Understanding the interplay between bevacizumab, hypoxia, and immune response is crucial for optimizing cancer therapy.
• Bevacizumab may offer dual benefits by enhancing ICI efficacy and potentially preventing hyperprogression.